x
Filter:
Filters applied
- Coronavirus (COVID-19) Collection
- VaccinationRemove Vaccination filter
- Diabetes Mellitus, Type 2Remove Diabetes Mellitus, Type 2 filter
- 2020 - 2022Remove 2020 - 2022 filter
Coronavirus (COVID-19) Collection
1 Results
- Short communicationOpen Access
Independent risk factors of COVID-19 pneumonia in vaccinated Mexican adults
International Journal of Infectious DiseasesVol. 118p244–246Published online: February 11, 2022- Efrén Murillo-Zamora
- Ramón Alberto Sánchez-Piña
- Xóchitl Trujillo
- Miguel Huerta
- Mónica Ríos-Silva
- Oliver Mendoza-Cano
Cited in Scopus: 4The availability of vaccines against coronavirus disease 2019 (COVID-19) represent a significant step toward ending the pandemic, and most COVID-19 vaccines confer close to 100% reduction in the risk of serious illness or death (Sharma et al. 2021). In Mexico, vaccination of the general population started in mid-February 2021, and by June 2021, 7 COVID-19 vaccines have received approval by health authorities for their application in Mexico: BNT162b2 (Pfizer, Inc./BioNTech), AZD1222 Covishield (AstraZeneca), Gam-COVID-Vac (National Center Gamaleya), CoronaVac (Sinovac Research and Development Co.), Ad5-nCoV Covidecia (CanSino Biologics Inc.), BBV152 Covaxin (Bharat Biotech International Limited), and Ad26.COV2-S (Janssen-Cilag).